 |
Corporate News
14-Mar-24
|
|
|
|
|
|
|
|
|
|
|
|
Zydus receives USFDA tentative approval for Edaravone Injection
|
|
|
|
|
|
|
|
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture and market Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial, (RLD: RADICAVA®).
Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).
Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), had annual sales of USD 19 mn. in the United States (IQVIA MAT Jan-24).
|
|
|
|
Previous News |
Zydus Lifesciences consolidated net profit rises 298.62% in the March 2024 quarter
(
Results
-
Announcements
17-May-24
16:25
)
|
|
|
Zydus' transdermal manufacturing site completes USFDA inspection
(
Corporate News
-
19-Jul-24
19:26
)
|
|
|
Zydus Lifesciences Ltd spurts 0.43%, up for five straight sessions
(
Hot Pursuit
-
08-Jul-24
13:01
)
|
|
|
Zydus Life arm inks pact to acquire 50% stake in Sterling Biotech
(
Hot Pursuit
-
24-Aug-24
13:52
)
|
|
|
Zydus Life gets tentative USFDA nod for hypertension drugs
(
Hot Pursuit
-
14-Jun-24
12:34
)
|
|
|
Zydus Lifesciences Ltd soars 1.83%, rises for third straight session
(
Hot Pursuit
-
08-Aug-24
13:05
)
|
|
|
Zydus Lifesciences consolidated net profit rises 26.76% in the December 2023 quarter
(
Results
-
Announcements
09-Feb-24
14:29
)
|
|
|
Zydus Lifesciences Ltd gains for third straight session
(
Hot Pursuit
-
02-Jan-24
13:05
)
|
|
|
Zydus acquires 50% stake in Sterling Biotech
(
Corporate News
-
24-Aug-24
11:33
)
|
|
|
Zydus Lifesciences Ltd soars 0.37%, rises for fifth straight session
(
Hot Pursuit
-
14-Feb-24
13:00
)
|
|
|
Board of Zydus Lifesciences recommends Final Dividend
(
Corporate News
-
17-May-24
16:18
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|